Inge Jedema

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 474 citations · Full text

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia

Dyantha I. van der Lee, Rogier M. Reijmers, Maria W. Honders et al. · Journal of Clinical Investigation · 2019 · 227 citations · Full text

New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population

Inge Jedema, Nicole M. van der Werff, Renée M. Y. Barge et al. · Blood · 2003 · 172 citations · Full text

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

Inge Jedema, Renée M. Y. Barge, Vincent H. J. van der Velden et al. · Leukemia · 2003 · 138 citations

Hematological Malignancy, Gemtuzumab Ozogamicin, Cell Cycle-dependent Killing +12

BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells

Sarah E. Alford, Anisha Kothari, Floris C. Loeff et al. · Cancer Research · 2015 · 122 citations · Full text

Bim Interaction, Mixed-phenotype Acute Leukemia, Bcl-2 Dependence +17